Skip to main content

FDA Approvals

Payers' Guide, FDA Approvals

Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer

Payers' Guide, FDA Approvals

Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma

Lisa A. Raedler, PhD, RPh

Idelalisib Approved for 3 Types of Hematologic Cancers

Belinostat Approved for Peripheral T-Cell Lymphoma

Palonosetron Indicated for CINV Prevention in Pediatric Patients

Zykadia for Metastatic, ALK-Positive Lung Cancer

Ramucirumab First Drug for Advanced Stomach Cancer

Ofatumumab Approved for Patients with CLL

Ibrutinib Approved for CLL

First Drug Combination Approved for Unresectable or Metastatic Melanoma

Page 44 of 53
Results 431 - 440 of 525